...
首页> 外文期刊>RSC Advances >Improving the anticancer activity of platinum(iv) prodrugs using a dual-targeting strategy with a dichloroacetate axial ligand
【24h】

Improving the anticancer activity of platinum(iv) prodrugs using a dual-targeting strategy with a dichloroacetate axial ligand

机译:使用双靶向策略提高铂(IV)前药的抗癌活性用二氯乙酸二氯乙酸轴配体

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Four novel platinum( IV ) complexes, characteristic of DCA/TFA and with chloride ions as axial ligands, were designed and synthesized. This type of platinum( IV ) complexes 1a–2b exhibited significant cytotoxic activity, and the cytotoxicity of 1b was the greatest among these four complexes, which was 20.61 fold and 7.65 fold higher than that of cisplatin against HepG-2 and NCI-H460 cancer cells, respectively. The result from the apoptosis assay of 1b was consistent with the result from the cytotoxicity assay. In addition, complexes 1a and 1b induced cell cycle arrest at the S phase on HepG-2 cells. Taken together, our data showed that Pt( IV ) complex 1b released the corresponding Pt( II ) complex and DCA, and induced apoptosis as well as disruption of the mitochondrial membrane potential, establishing Pt( IV ) complex 1b as a potential dual-targeting anticancer agent.
机译:设计并合成了四种新型铂(IV)复合物,DCA / TFA的特征和作为轴向配体的氯离子。这种类型的铂(IV)复合物1a-2b表现出显着的细胞毒性活性,并且1b的细胞毒性在这四个络合物中最大,其比率为20.61倍,比顺铂对抗HepG-2和NCI-H460癌症的7.65倍细胞分别。 1B的凋亡测定的结果与来自细胞毒性测定的结果一致。此外,复合物1a和1b在hepg-2细胞上的S期诱导细胞周期停滞。我们的数据表明,Pt(iv)复合物1b释放了相应的pt(ii)复合物和dca,以及诱导的细胞凋亡以及线粒体膜电位的破坏,建立Pt(iv)复合物1b作为潜在的双靶点抗癌剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号